TRIAL MASTER FILE PLAN

STUDY NUMBER: Vedolizumab-4071

STUDY-SPECIFIC VERSION/DATE: Version 1.0 dated 06 May 2026

1. INTRODUCTION AND PURPOSE

The purpose of the Trial Master File (TMF) Plan is to describe the responsibilities and requirements related to TMF set-up, maintenance and reconciliation throughout the course of this clinical trial. This Plan will include TMF components outsourced to Clinny Biotech Limited (ClinnyBio), vendors, and sponsor documentation.

The procedures defined in this plan are written to ensure compliance with applicable global Regulatory Authority's requirements, the International Conference on Harmonization (ICH) and Good Clinical Practices (GCP), relevant SOPs and agreements.

2. CLINICAL TRIAL INFORMATION

Current study timelines will be available in the Sponsor's CTMS system. Study-specific clinical trial information is listed in Attachment 1, including Takeda SharePoint folder and TMF Index version (as applicable).

3. DEFINITIONS

Sponsor	Responsible for ensuring that a clinical trial complies with the legislation and GCP.
CRO Partner	An organization that provides support to the pharmaceutical, biotechnical, and medical device industries in the form of research services outsourced on a contract basis. Contract Research Organization (CRO)
Vendors	All the various types of providers to which a sponsor may delegate certain functions of the clinical trial (i.e., laboratories, consultants).
TMF/Electronic TMF (eTMF)	Essential documents within the trial-specific TMF owned by relevant functional groups within the trial-specific team. The essential documents collectively permit evaluation of the conduct of a trial and the quality of the data produced.
Study-Specific TMF Index	A comprehensive list of all expected documents within a clinical trial. It provides detailed information related to each document type, such as zone/section, document owner, responsible function (including that of the CRO, where applicable), document format, system of record, and the location of the document during and after trial. May be referred to as TMF Specifications, Reference Model or TMF Roadmap (RM).
TMF Plan	A document that describes the trial-specific team's plan for maintenance and oversight of the trial-specific TMF from set up to archive.
TMF Contributor	Document owner, designated by the Study-Specific TMF Roadmap / TMF Index / TMF Reference Model, responsible of ensuring the TMF quality and filing of specific TMF documents. Often referred to as Study Team members and/or functional area representatives.
Audit	Quality audit is a systematic and independent examination to determine whether activities and related results comply with regulations, SOPs and procedures, conducted by Sponsor and CRO Partner (as applicable) Quality Assurance/Compliance department.

Quality Check (QC)	Periodic checks of the TMF to ensure proper filing, naming, etc. according to the study-specific TMF Index and compliance with SOPs, applicable procedures, and regulations.
Archive	A file or place for long term, orderly storage and expedient retrieval of raw data, documentation, protocols and interim or final reports no longer in active use.

4. TMF ACCOUNTABILITY AND RESPONSIBILITY

Takeda is responsible to oversee the management of the TMF. Takeda may contract a CRO Partner to hold the TMF which would be documented in the contractual obligation; however, Takeda is still responsible for overall oversight of the TMF. Study team members will participate in the management of the TMF in accordance with SOPs and procedures outlined in Section 6 as well as requirements defined in this plan. TMF portions managed by ClinnyBio will be documented within the Study-Specific TMF Index.

Task	Milestone (to trigger)	Owner
Develop TMF Plan and Attachments based on general study discussion	To be completed by FPFV	CRO Partner Study Management with collaboration from Clinical Operations representative
Develop & finalize TMF Index (or equivalent)	To be completed by FPFV (This document had been finalized during study start-up period.)	Sponsor and CRO Partner Study Team in collaboration
Set up TMF structure in Takeda SharePoint based on Study-Specific TMF Index	Finalized TMF Index (The document folder had been set-up during study start-up period)	CRO Partner Study Management
Update TMF Index (or equivalent structure), as needed throughout lifecycle of study	Ongoing	Sponsor and CRO Partner Study Team in collaboration
File/Submit Sponsor TMF documentation	Ongoing (per SOP requirements)	Sponsor Study Team
File/Submit CRO maintained TMF throughout lifecycle of study	Ongoing, the batch of e-documents will be provided by CRO to Sponsor monthly and the wet-ink documents will be provided after study completion.	CRO representative to facilitate.
Conduct QC completeness of CRO maintained TMF documentation	CRO perform document QC after LPLV.	CRO Partner Study Management
Perform oversight of CRO TMF documentation and conduct QC completeness of TMF documentation	Ongoing	Sponsor representative

Task	Milestone (to trigger)	Owner
Conduct final QC completeness of CRO maintained TMF documentation	Final CRO QC will be performed within 30 working days after study report finalized.	CRO Partner Study Management
Request provide of Final TMF Documents	30 working days after final CSR	Sponsor representative /CRO Partner Study Management
Confirm QC review of TMF and document findings	Final QC	Sponsor representative
Resolve TMF quality control findings and create TMF documentation/confirmation of completeness	Complete TMF	CRO Partner Study Management
Review and approve TMF documentation/confirmation of completeness	Complete TMF	Sponsor representative /CRO Partner Study Management
Provide final TMF documentation to Takeda	Within 90 days of CSR	CRO Partner Study Management
Archive TMF documents	Complete TMF	Sponsor representative

5. ESCALATION PATHWAY

The study team is responsible to escalate issues as they arise. Escalation management is documented in the Study Monitoring Report, communication section.

6. TMF SOP REQUIREMENTS

Management of the TMF will be governed by:

Company	SOP Number	SOP Title
Takeda	PROC-0002552	Trial Master File
Clinny Biotech Limited	SOP 006	Management of Trial Master File Documents For Clinical Trial

7. STORAGE FORMAT AND TMF LOCATION

The document location and document format (paper or electronic) is outlined in the study-specific TMF Index.
The study-specific TMF Index outlines responsible function (Sponsor or vendor), document location including document format and system(s) of record.
The TMF deliverable for Takeda maintained documents is detailed in the study-specific TMF Index.
The TMF deliverable for ClinnyBio components is for both paper and electronic documents according to TMF Index.

7.1. SYSTEMS OF RECORDS

Majority of content will be held in eTMF location(s); however, there may be document types held in other systems to support the business need and requirements. Potential documentation sources are listed below. Systems utilized for this study are outlined in Attachment 3.

TMF Location/System	Documentation	Responsible Party/Function
eTMF/ Microsoft 365 SharePoint	Defined in the study specific TMF Index	ClinnyBio study team
SAS	Datasets, validation documentation, etc.	ClinnyBio Biostatistics

8. TMF ORGANIZATION

8.1. STUDY SPECIFIC TMF STRUCTURE

The study-specific TMF Index will be created at the beginning of the study and will detail document types held by Takeda and ClinnyBio. The study-specific TMF Index acts as the reference document regarding document location and format for all TMF documents for the study. The study-specific TMF Index will be reviewed throughout the study to ensure accuracy and allow for any changes, as required. Final versions of the study-specific TMF Index will be distributed to the study team and ClinnyBio that are responsible for TMF content. Final versions of the study-specific TMF Index will be filed within the TMF.
ClinnyBio portion of the TMF will follow their TMF structure for filing, per Takeda and ClinnyBio SOPs listed in Section 6. This will include the defined structure and organization of the files and their contents and will be consistent with the study-specific TMF Index in regards to document types required to be held by ClinnyBio. ClinnyBio TMF structure will also contain any document types required per their SOPs/processes.
If updates are required to be made to either the study-specific TMF Index or ClinnyBio TMF filing structure, appropriate representatives from Takeda and ClinnyBio must review the proposed changes and the changes should be consistent across both lists prior to approval, as applicable.
The TMF Structure will follow Takeda TOOL-0001336 Trial Master File Index and set up in Microsoft Share Point.

9. SECURE STORAGE

The TMF (eTMF and any paper wet ink originals) will be maintained via a secure storage.

9.1. eTMF

- Takeda SharePoint administration will be managed by Takeda representatives and the authorization should be controlled according to ClinnyBio team list.

9.2. Paper

- Where original wet ink signature documents are retained the TMF documents must be maintained in a secure, fire resistant environment that prevents unauthorized access.
- Documents must be protected from untimely deterioration (e.g., by keeping out of direct sunlight). Transfer of documents should be properly controlled through the utilization of secure transport methods and their electronic tracking systems.
- Paper TMF documents will be organized according to each organization's applicable SOPs and processes.

10. DOCUMENT SIGNATURES

10.1. Wet ink signatures

Wet ink signatures are retained and managed per Company SOPs, local laws, and regulations. Wet ink signatures created from ClinnyBio or at the site-level should be retained at the source of origin (i.e., site staff CVs, retain at the site; CRO Partner wet inks, retain per Company SOPs, local laws and regulations).

Where a wet ink is created by Takeda, Takeda will retain the wet inks appropriately per SOP requirements and regulations and this will be documented on the study-specific TMF Index.

10.2. Electronic signatures

Electronic signatures are permitted per each company's SOPs, local laws and regulations. Electronic signatures must also be in compliance with FDA CFR 21 Part 11, which has specific requirements including the requirement for a validated system.

11. DOCUMENT TRANSLATION REQUIREMENTS

Documents requiring translation and additional translation requirements for this study are documented below.

Translation Types

A	Certified translation (incl. CoT) by translation agency
B	Validation (CoV) by translation agency
C	CLINNYBIO certified translation (incl. CoT)
D	CLINNYBIO validation (CoV) of certified translation

Translation Companies

Company Name **EVERMORE Translation Service (宏茂翻譯股份有限公司)**	**Contact Info** **8F, No. 218, Sec. 3, New Taipei Blvd., Xinzhuang Dist., New Taipei City 242032, Taiwan (R.O.C.)**		
Document	**Countries**	**Type of Translation**	**Comments**
Protocol Synopsis	countries needing translation	C + D	
Clinical Site Agreement (CSA)	All countries/sites where the signed CSA is not in English	A + B/ C + D	If any CSA and CSA amendment in English, the document has to be translated to Traditional Chinese and bilingual document will be used and filed. Document template will be translated by translation vendor and changes required during contract negotiation will be translated by ClinnyBio representatives.
ICF – country / site specific versions	All countries	C + D	The study only involves one country that core ICF is equal to country ICF. Only Core ICF will be translated from English to Traditional Chinese. Site ICFs will be customized from Traditional Chinese Core ICF to Site level ICF and no translation is required.
EC approvals	All countries when requested by sponsor	A + B	If independent EC does not provide the English version approval, it should be translated.
CVs	All countries	C + D	
SAE source docs e.g medical narratives	All countries needing translation	A or C	
SAE Regulatory reports (CIOMS/MedWatch)	All countries needing translation	A or C	
Clinical Study Report (CSR)	-	A + B	

12. RELEVANT CORRESPONDENCE MANAGEMENT

Relevant correspondence is necessary for reconstruction of key trial conduct activities and decisions and/or other significant information and must be retained in the TMF. Mass communication to site distribution list must be created to document that all appropriate sites received the information (if applicable).

Key study-related decisions should be documented as soon as possible and filed in the relevant TMF section in a timely manner. The documentation should include the rationale behind the decision and allow reconstruction of the decision-making process. Key decisions and discussions may include, but is not limited to:

- Implementation of an urgent safety measure
- Rationale to support why a course of action was taken
- Training of new team members
- Implementation and training of amendments to the trial team
- Communications with support functions and departments

Key study-related decisions can be documented in clear, concise emails and letters, site contact report forms, telephone contact logs, etc. Key study-related decisions should include details of who made the decision and when it was made. The document (email, letter, etc.) author and originator of the key business decision must submit the documentation to the TMF to be filed appropriately.

13. CERTIFIED COPIES

Where original paper TMF documents are transferred to an electronic format, the system of transfer should be validated in order to ensure the authenticity of scanned images as certified copies. A certified copy can replace the original paper record and the following requirements should be adhered to.

- Accuracy of the metadata attributed to the document; quality of indexing
- Quality of the image (readability, quality of wet ink signature, etc.)
- Scanned images are at appropriate resolution, when viewed at actual size the image is clear and legible
- Correct (expected) document
- Correct number of pages
- eTMF audit trail associated with the document
- Chain of records transfer documentation

- QC process
- The original paper TMF documents will be transferred to e-TMF documents and the original one will also be archived for 10 years after study completion.

14. TMF ACCESSIBILITY DURING THE TRIAL

The study-specific TMF Index acts as the reference document regarding document location and format for all TMF documents for the study.

14.1. TMF CONTENT

ETMF content is accessible electronically during the conduct of the trial by ClinnyBio study team members. ClinnyBio may have internal non-TMF documentation which is retained according to ClinnyBio SOPs and polices and will remain with ClinnyBio upon study close out according to their retention period.

ETMF access will be managed by Takeda in accordance with their SOPs and processes.

15. DOCUMENT SUBMISSION PROCESS AND TIMELINESS

15.1. CONTENT MANAGED BY CLINNYBIO

ClinnyBio will process documents according to applicable SOPs and processes (see Section 6).

The document which needs to be translated per section 15 will be combined with translated document, COT, and COV (if applicable) and filed in TMF.

16. TMF COMPLETENESS / QUALITY REVIEWS

Oversight of the TMF is ongoing for the duration of the trial to ensure completeness. Quality review timing and scope of review will be determined per each company's SOPs, and documented per study in Attachment 2.

16.1. QC DOCUMENTATION

Takeda QC of the TMF

Per the Takeda Trial Master File SOP, PROC-0002552, quality reviews are to be conducted to confirm all documents are complete, of good quality, and are filed in the correct location per the study-specific TMF Index.

- Quality checks to be conducted by each applicable functional area representative at designated study milestones as indicated in attachment 2.
- Final quality review documentation must be filed to the TMF that indicates that all documents are present, complete, and of good quality and are filed in their final archive locations per the study-specific TMF Index.
- Quality review documentation will be filed at Takeda within the TMF, with Takeda functional area representative signature and date.

ClinnyBio QC of the eTMF

Essential and critical documents should be complete, legible, accurate, unambiguous, and authentic. The TMF must be subject to ongoing quality review checks to ensure the quality and integrity of the trial, as follows:

- ClinnyBio will perform quality review checks per ClinnyBio SOPs.
- All finalized documents cited in the study-specific TMF Index must be reviewed and the review must be documented.
- Quality review documentation should be submitted to Takeda within 10 business days of the review being carried out. Any issues identified must be resolved and the review documentation updated and submitted to Takeda. All issues should be resolved within 30 business days from the date the review documentation was received at Takeda, with monthly updates provided by ClinnyBio during the issue resolution period. Final quality review documentation must be filed according to the agreed file structure, with ClinnyBio signature and date.

17. TMF AUDITS / INSPECTIONS

The TMF may be audited by Takeda Quality Assurance representatives and documented/filed according to applicable SOPs and processes.

17.1. AUDITOR/INSPECTOR TMF ACCESS AND AVAILABILITY

During the trial, eTMF expedited access would be provided to the auditor and/or inspector.

Should the audit and/or inspection be conducted onsite at Takeda or ClinnyBio, the following requirements should be followed.

- As some auditors and/or inspectors require direct access into the eTMF system, very brief training or familiarization for the eTMF should be provided to the auditor and/or inspector.
- Suitable equipment for the auditor and/or inspector to view documents at an actual size and ability to compare documents side by side.
- Facilities to allow for the auditor and/or inspector to copy and retain documents from the eTMF.

18. TMF CONSOLIDATION / CLOSE-OUT PROCESS

Following approval of the Clinical Study Report, all sections of the TMF, with the exception of those files held by the Investigator/Institution should be brought together for archive. ClinnyBio and Takeda portions of the TMF will remain as separate entities to ensure document mapping structure is not compromised.

ClinnyBio Requirements

Documents that are required to be returned to Takeda at the end of the study are listed in the final study-specific TMF Index.

A final quality review and consolidation should be performed by ClinnyBio to ensure all documents are present as specified in the study-specific TMF Index. The percent of the final review must be agreed by the Sponsor and the review must be documented and signed off as the final review by ClinnyBio. ClinnyBio signature of the

final review will serve to confirm all documents listed in the study-specific TMF Index are present and complete.

Upon Takeda review of this documentation, Takeda will provide written authorization to confirm ClinnyBio is approved to prepare the eTMF for lock and to prepare any wet inks for shipment to Takeda in an "archive-ready" state.

18.1. TRIAL MASTER FILE ARCHIVE PREPARATION (ETMF AND WET INK ORIGINALS)

A copy of the eTMF should be stored in a hard drive and/or CD with password encrypted.

- ClinnyBio will archive the documents in study-specific TMF index.
- A master inventory for the eTMF content (folder structure) must be sent to Takeda separately which will be consistent with the folder structure in Takeda's SharePoint.

ClinnyBio Wet ink originals must be shipped to Takeda in an "archive-ready" state, as follows:

- Files must be removed from any form of binding (i.e., plastic wallets) and transferred to accordio files suitable for archive, but maintaining the filing structure order.
- A master inventory for the entire shipment and File Table of Contents must be sent to Takeda separately.

18.2. CHAIN OF CUSTODY

ClinnyBio will inform Takeda when any paper document shipped to Takeda via courier by e-mail with a document list. Takeda will reconciliate between received documents and the document list and confirm the proper receiving, damaging, or missing and sending back the signed list to ClinnyBio via paper document or e-document for filing.

ClinnyBio will provide further document if any e-file damaged and/or any missing document until all problems resolved.

The TMF (electronic and paper, wet ink originals) must be returned via courier, direct to Takeda, addressed as follows to the attention of:

Takeda Pharmaceuticals Taiwan Limited
Minna Chen, Senior Real World Evidence Scientist 17F., No.1, Songgao Road, Xinyi Dist., Taipei City 11073, Taiwan. Chen, Minna <minna.chen@takeda.com>

19. ARCHIVE

Following the final consolidation activities, all TMF documents are received at Takeda, secured, and prepared for archival for the retention timeline outlined in Takeda's Record Retention Schedule to ensure that legal, regulatory and business requirements are met and that the documentation is protected and maintained as required.

Takeda has appointed individuals who are responsible for archiving the TMF. Access to these documents is restricted to these appointed individuals. Documentation to support the appointment and appropriate training, and subsequent training records, are available upon request.

Takeda utilizes an external archive facility in different geographical locations and maintains records from the archive, transfer of documentation to/from the archive facility, which are controlled and overseen by the appointed Sponsor archivists.

19.1. INVESTIGATOR / INSTITUTION'S CONFIDENTIAL RECORDS

The ultimate responsibility for the documents to be retained by the investigator and/or institution resides with the investigator and/or institution. Document retention requirements are outlined in ICH-GCP, regulations and local country requirements. It is the investigator and/or institution's responsibility to ensure the confidential records are retained appropriately. If the investigator becomes unable to be responsible for the records (i.e., retirement), the Sponsor should be notified in writing and informed to whom the responsibility has been transferred to.

20. REFERENCES

(i) Reflection paper on GCP compliance in relation to TMF (paper and/or electronic) for management, audit and inspection of clinical trials [EMA/INS/GCP/636736/2012]

(II) MHRA Good Clinical Practice Guide, 10.7.1

(iii) Good Clinical Practice (CPMP/ICH/GCP/135/95)

(iv) International Conference on Harmonisation/Good Clinical Practice E-6 Rev.2

21. TMF PLAN APPROVAL SIGNATURES

Takeda Clinical Operations representative
Name: Minna Chen
Title: Senior Real World Evidence Scientist

By signing below, I indicate that I have reviewed the content of this document and its attachments, and I find it to be correct and complete.

Signed by:
Minna Chen 20-May-2026 | 12:18:27 IST

Signature: Signer Name: Minna Chen
Signing Reason: I approve this document
Signing Time: 20-May-2026 | 12:17:46 IST
B3F875263D9E4D7E8BE92082E0995901 Date

CRO Project Manager
Name: Helium Wang
Title: Clinical Research Manager

By signing below, I indicate that I have reviewed the content of this document and I find it to be acceptable.

Signature: Signed with Odoo Sign Helium Wang 27076e051d... Date 2026/05/20

CRO TMF Owner/TMF Specialist
Name: Phoebe Chang
Title: Assistant

By signing below, I indicate that I have reviewed the content of this document and I find it to be acceptable.

Signature: Signed with Odoo Sign Phoebe Chang 968ab211cf... Date 2026/05/20

22. TRIAL MASTER FILE PLAN - ATTACHMENT APPROVAL SIGNATURES

Protocol Number: Vedolizumab-4071

By signing below, I indicate that I have reviewed the below listed TMF Plan attachment plans for this study and confirm I find them to be acceptable:

- ☐ Attachment 1: Study-Specific TMF Related Information – **Version/Date: Version 1.0 dated 06 May 2026**
- ☐ Attachment 2: QC Schedule – **Version/Date: Version 1.0 dated 06 May 2026**
- ☐ Attachment 3: Study-Specific Systems of Record – **Version/Date: Version 1.0 dated 06 May 2026**

Takeda

Printed Name: Minna Chen Title: Senior Real World Evidence Scientist

Signature: Signed by: Minna Chen Signer Name: Minna Chen Signing Reason: I approve this document Signing Time: 20-May-2026 | 12:18:10 IST B3F875263D9E4D7E8BE92082E0995901 Date: 20-May-2026 | 12:18:27 IST

CRO Partner

Printed Name: Helium Wang Title: Clinical Research Manager

Signature: Signed with Odoo Sign Helium Wang 27076e051d... Date: 2026/05/20

ATTACHMENT 1 – STUDY-SPECIFIC TMF-RELATED INFORMATION

Protocol Number	Vedolizumab-4071
Protocol Title	A Multi-Centre, Non-Interventional, Retrospective Chart-Review Study: The Real-World Comparative Effectiveness of Ulcerative Colitis and Crohn's Disease Patients with Advanced Treatments and Impact of Treatment Forced Discontinuation in Taiwan
Study Phase	Retrospective
Study Duration	18 months
Approximate Number of Sites Planned	6
Planned Countries	Taiwan
Services outsourced to CRO (if applicable)	Full services from protocol design to study close-out.
CTOM Model	☐ Phase I Single-Center, Healthy Volunteers (non-outsourced) ☐ Phase I Multi-Center Low Complexity (outsourced) ☐ Baseline (outsourced Phase II-IV interventional) ■ RWLP (Real World Late Phase) ☐ Any adaptations expected: _____
IND or Non-IND	☐ IND ■ Non-IND
Interventional or Non-Interventional	☐ Interventional ■ Non-Interventional
CRO's eTMF System and version (if applicable)	Microsoft 365 SharePoint
CRO's Master TMF Table of Contents version (if applicable)	NAP
Study-Specific TMF Index version/date	Version 1.0 dated 21 Nov 2025

ATTACHMENT 2 – QC SCHEDULE

Takeda QC Schedule

Review #	Associated Milestone	Planned Date
Final QC	CSR	30 Apr 2027

ClinnyBio **QC Schedule (if applicable)**

Review #	Planned Date
1	FPFV – 31 Aug 2026
2	31 Dec 2026
Final QC	31 Mar 2027

ATTACHMENT 3 – STUDY-SPECIFIC SYSTEMS OF RECORD

TMF Location/System	Documentation	Responsible Function/Company
Takeda SharePoint eTMF	Defined in the study specific TMF Index	ClinnyBio study team
SAS	Datasets, validation documentation, etc.	ClinnyBio Statistics

Certificate Of Completion

Envelope Id: 4BD1BCB1-4798-888B-81FD-91FD41F3C26B
Status: Completed
Subject: Complete with Docusign: Vedolizumab-4071_TWN Master TMF Plan Version 1.0 dated 06 May 2026_Clea...
Department: GEM Quality
Document Type: Form
Source Envelope:
Document Pages: 17
Signatures: 2
Certificate Pages: 2
Initials: 0
AutoNav: Enabled
EnvelopeId Stamping: Enabled
Time Zone: (UTC+05:30) Chennai, Kolkata, Mumbai, New Delhi

Envelope Originator:
Minna Min Chen
40 Landsdowne Street
Cambridge, MA 02139
minna.chen@takeda.com
IP Address: 167.103.160.90

Record Tracking

Status: Original
5/20/2026 12:14:40 PM
Holder: Minna Min Chen
minna.chen@takeda.com
Location: DocuSign

Signer Events	Signature	Timestamp
Minna Chen minna.chen@takeda.com Real World Evidence Scientist Security Level: Email, Account Authentication (Required)	Signed by: Minna Chen Signer Name: Minna Chen Signing Reason: I approve this document Signing Time: 20-May-2026 | 12:17:46 IST B3F875263D9E4D7E8BE92082E0995901 Signature Adoption: Pre-selected Style Signature ID: B3F87526-3D9E-4D7E-8BE9-2082E0995901 Using IP Address: 167.103.160.90 With Signing Authentication via Docusign password With Signing Reasons (on each tab): I approve this document I approve this document	Sent: 5/20/2026 12:17:05 PM Viewed: 5/20/2026 12:17:18 PM Signed: 5/20/2026 12:18:27 PM

Electronic Record and Signature Disclosure:
Not Offered via Docusign

In Person Signer Events	Signature	Timestamp

Editor Delivery Events	Status	Timestamp

Agent Delivery Events	Status	Timestamp

Intermediary Delivery Events	Status	Timestamp

Certified Delivery Events	Status	Timestamp

Carbon Copy Events	Status	Timestamp

Witness Events	Signature	Timestamp

Notary Events	Signature	Timestamp

Envelope Summary Events	Status	Timestamps
Envelope Sent	Hashed/Encrypted	5/20/2026 12:17:05 PM
Certified Delivered	Security Checked	5/20/2026 12:17:18 PM

Envelope Summary Events	Status	Timestamps
Signing Complete	Security Checked	5/20/2026 12:18:27 PM
Completed	Security Checked	5/20/2026 12:18:27 PM

Payment Events	Status	Timestamps